Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov;68(11):807-814.
doi: 10.46747/cfp.6811807.

Individualized antidepressant therapy in patients with major depressive disorder: Novel evidence-informed decision support tool

Tracy Chin  1 , Trudy Huyghebaert  2 , Clark Svrcek  3 , Oloruntoba Oluboka  4
Affiliations
Review

Individualized antidepressant therapy in patients with major depressive disorder: Novel evidence-informed decision support tool

Tracy Chin et al. Can Fam Physician. 2022 Nov.

Abstract

Objective: To introduce a visual clinical decision support tool to assist with individualizing first-line antidepressant pharmacotherapy for adults with major depressive disorder (MDD) in a Canadian context.

Sources of information: A literature review was conducted with Google Scholar, PubMed, the Cochrane Database of Systematic Reviews, and Trip Pro using the MeSH headings depression, antidepressive agents, primary care, practice patterns, medication adherence, and decision making, shared.

Main message: Major depressive disorder affects about 4.7% of Canadians annually and is a prevalent condition encountered and diagnosed in primary care. Untreated depression is associated with decreased quality of life, increased risk of suicide, and worsening physical health outcomes when depression co-occurs with other chronic medical conditions. In a network meta-analysis, antidepressant medications (such as selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, bupropion, and vortioxetine) reduced depressive symptoms by 50% or more when compared with placebo in acute treatment of adults with moderate to severe MDD. Poor treatment adherence and high discontinuation rates limit MDD treatment success. Factors such as strong therapeutic alliances between patients and prescribers, collaborative care, patient education, and supportive self-management have been shown to enhance treatment adherence. The most recent Canadian Network for Mood and Anxiety Treatments depression treatment guidelines (published in 2016) suggest 15 different first-line antidepressant medication options for the treatment of MDD. There is a need for evidence-informed decision support aids to individualize antidepressant therapy to treat patients diagnosed with MDD.

Conclusion: Recent studies on antidepressants have indicated no single antidepressant is superior to others in treating patients with MDD. This suggests there may be opportunities to enhance treatment adherence and success by tailoring antidepressant therapy to align with each patient's preferences. The Antidepressant Decision Support Tool was developed to help prescribers and adult patients engage in shared decision making to select an individualized and optimal first-line antidepressant for the treatment of acute MDD.

PubMed Disclaimer

Figures

Figure 1A.
Figure 1A.
Antidepressant Decision Support Tool: Stage 1—adult depression antidepressant treatment based on efficacy and comorbidities.
Figure 1B.
Figure 1B.
Antidepressant Decision Support Tool: Stage 2—considerations in antidepressant decision making.
See this image and copyright information in PMC

References

    1. Lam RW, McIntosh D, Wang J, Enns MW, Kolivakis T, Michalak EE, et al. . Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 1. Disease burden and principles of care. Can J Psychiatry 2016;61(9):510-23. Epub 2016 Aug 2. - PMC - PubMed
    1. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. . Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396(10258):1204-22. Erratum in: Lancet 2020;396(10262):1562. Epub 2020 Oct 23. - PMC - PubMed
    1. Daly EJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Gaynes BN, Warden D, et al. . Health-related quality of life in depression: a STAR*D report. Ann Clin Psychiatry 2010;22(1):43-55. - PubMed
    1. Rihmer Z, Gonda X.. Prevention of depression-related suicides in primary care. Psychiatr Hung 2012;27(2):72-81. - PubMed
    1. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B.. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007;370(9590):851-8. - PubMed

Substances